SilverCrest Metals
SILV
Collegium Pharmaceutical
COLL
Cars.com
CARS
Halozyme Therapeutics
HALO
Hutchmed (China)
HCM
(Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 71.68%891K | 605K | 0 | 886K | 367K | 519K | 0 | 0 | 0 | 0 |
Operating revenue | 71.68%891K | --605K | --0 | --886K | --367K | --519K | --0 | --0 | --0 | --0 |
Cost of revenue | -81.17%170K | 1.85M | 0 | 2.37M | 1.47M | 903K | 0 | 0 | 0 | 0 |
Gross profit | 287.76%721K | -1.24M | 0 | -1.49M | -1.1M | -384K | 0 | 0 | 0 | 0 |
Operating expense | -9.36%43.86M | -42.97%41.95M | -23.16%62.65M | -47.45%266.33M | -24.43%62.85M | -55.75%48.39M | -57.60%73.57M | -42.09%81.53M | 12.65%506.8M | -41.21%83.17M |
Selling and administrative expenses | -9.31%22.6M | -28.33%21.8M | 10.11%32.87M | -42.20%113.3M | -22.86%28.1M | -48.95%24.93M | -44.84%30.42M | -46.34%29.85M | 0.66%196.03M | -28.10%36.43M |
Research and development costs | -20.32%17.5M | -56.50%16.78M | -43.98%26.39M | -53.48%139.19M | -28.65%31.54M | -61.51%21.97M | -66.58%38.58M | -42.90%47.1M | 21.51%299.22M | -49.88%44.21M |
Depreciation amortization depletion | 150.97%3.75M | -26.26%3.36M | -25.90%3.39M | 19.81%13.84M | 26.72%3.21M | -56.65%1.5M | 57.75%4.56M | 70.84%4.58M | 29.51%11.55M | -2.69%2.53M |
-Depreciation and amortization | 150.97%3.75M | -26.26%3.36M | -25.90%3.39M | 19.81%13.84M | 26.72%3.21M | -56.65%1.5M | 57.75%4.56M | 70.84%4.58M | 29.51%11.55M | -2.69%2.53M |
Operating profit | 11.55%-43.14M | 41.29%-43.19M | 23.16%-62.65M | 47.15%-267.82M | 23.10%-63.96M | 55.40%-48.77M | 57.60%-73.57M | 42.09%-81.53M | -12.65%-506.8M | 41.21%-83.17M |
Net non-operating interest income expense | 42.84%-2.4M | 31.49%-1.55M | -1,800.00%-5.62M | -146.20%-5.54M | 2,130.00%1.22M | -92.52%-4.2M | -12,015.79%-2.26M | -920.69%-296K | -2,283.50%-2.25M | -350.00%-60K |
Non-operating interest expense | -42.84%2.4M | -31.49%1.55M | 1,800.00%5.62M | 146.20%5.54M | -2,130.00%-1.22M | 92.52%4.2M | --2.26M | 920.69%296K | --2.25M | --60K |
Other net income (expense) | 182.69%48.79M | 702.24%39.78M | -376.15%-42.42M | -234.22%-28.67M | 1,042.37%34.29M | -853.62%-59.01M | -45.46%4.96M | -157.66%-8.91M | -79.27%21.36M | -10.23%3M |
Gain on sale of security | 362.18%61.77M | 759.11%48.31M | -154.61%-9.47M | --62.72M | --26.39M | --13.37M | --5.62M | --17.34M | ---- | ---- |
Special income (charges) | -678.86%-17.87M | 101.24%11K | 201.06%24.49M | -229.54%-27.75M | -112.37%-327K | 62.77%-2.29M | -109.40%-890K | -256.70%-24.23M | -79.49%21.42M | -19.39%2.64M |
-Less:Restructuring and merger&acquisition | 5,854.48%16.06M | 74.58%-15K | 98.96%-26K | 88.59%-2.97M | 95.94%-129K | -113.50%-279K | 99.38%-59K | 83.80%-2.51M | 75.06%-26.04M | 3.20%-3.18M |
-Less:Other special charges | -29.58%1.81M | -99.58%4K | -191.50%-24.47M | 564.01%30.72M | -14.12%456K | -37.17%2.57M | --949K | --26.74M | --4.63M | --531K |
Other non- operating income (expenses) | 106.98%4.89M | -3,876.99%-8.54M | -2,749.01%-57.44M | -102,550.00%-63.64M | 2,198.32%8.23M | -269,442.31%-70.08M | 159.79%226K | -11,758.82%-2.02M | -127.68%-62K | 459.38%358K |
Income before tax | 102.91%3.26M | 93.00%-4.96M | -21.99%-110.69M | 38.07%-302.02M | 64.55%-28.45M | 4.87%-111.97M | 56.89%-70.87M | 27.63%-90.73M | -40.64%-487.69M | 41.91%-80.23M |
Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income | 102.91%3.26M | 93.00%-4.96M | -21.99%-110.69M | 38.07%-302.02M | 64.55%-28.45M | 4.87%-111.97M | 56.89%-70.87M | 27.63%-90.73M | -40.64%-487.69M | 41.91%-80.23M |
Net income continuous Operations | 102.91%3.26M | 93.00%-4.96M | -21.99%-110.69M | 38.07%-302.02M | 64.55%-28.45M | 4.87%-111.97M | 56.89%-70.87M | 27.63%-90.73M | -40.64%-487.69M | 41.91%-80.23M |
Minority interest income | ||||||||||
Net income attributable to the parent company | 102.91%3.26M | 93.00%-4.96M | -21.99%-110.69M | 38.07%-302.02M | 64.55%-28.45M | 4.87%-111.97M | 56.89%-70.87M | 27.63%-90.73M | -40.64%-487.69M | 41.91%-80.23M |
Preferred stock dividends | 1.24M | 1.08M | 862K | 600K | ||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | 101.81%2.02M | 91.48%-6.04M | -22.94%-111.55M | 37.95%-302.62M | 63.80%-29.05M | 4.87%-111.97M | 56.89%-70.87M | 27.63%-90.73M | -40.64%-487.69M | 41.91%-80.23M |
Basic earnings per share | 100.72%0.6 | 97.20%-1.8 | 55.91%-44 | 70.72%-243.8 | 100.17%0.2 | 58.04%-83 | 79.41%-64.4 | 59.82%-99.8 | -19.08%-832.6 | 58.33%-115 |
Diluted earnings per share | 100.72%0.6 | 97.20%-1.8 | 55.91%-44 | 70.72%-243.8 | 100.17%0.2 | 58.04%-83 | 79.41%-64.4 | 59.82%-99.8 | -19.08%-832.6 | 58.33%-115 |
Dividend per share | ||||||||||
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | -- | -- |